In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP...

Full description

Bibliographic Details
Main Authors:	Meiou Dai, Gang Yan, Ni Wang, Girija Daliah, Ashlin M. Edick, Sophie Poulet, Julien Boudreault, Suhad Ali, Sergio A. Burgos, Jean-Jacques Lebrun
Format:	Article
Language:	English
Published:	Nature Publishing Group 2021-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-021-23316-4

id	doaj-38501aae84394eee911b035fc5797ebd
record_format	Article
spelling	doaj-38501aae84394eee911b035fc5797ebd2021-05-30T11:15:05ZengNature Publishing GroupNature Communications2041-17232021-05-0112111810.1038/s41467-021-23316-4In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapyMeiou Dai0Gang Yan1Ni Wang2Girija Daliah3Ashlin M. Edick4Sophie Poulet5Julien Boudreault6Suhad Ali7Sergio A. Burgos8Jean-Jacques Lebrun9Department of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Animal Science, McGill UniversityDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Medicine, McGill University Health Center, Cancer Research ProgramDepartment of Animal Science, McGill UniversityDepartment of Medicine, McGill University Health Center, Cancer Research ProgramTriple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP reduces tumour growth in vivo.https://doi.org/10.1038/s41467-021-23316-4
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun
spellingShingle	Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy Nature Communications
author_facet	Meiou Dai Gang Yan Ni Wang Girija Daliah Ashlin M. Edick Sophie Poulet Julien Boudreault Suhad Ali Sergio A. Burgos Jean-Jacques Lebrun
author_sort	Meiou Dai
title	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_short	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_full	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_fullStr	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_full_unstemmed	In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy
title_sort	in vivo genome-wide crispr screen reveals breast cancer vulnerabilities and synergistic mtor/hippo targeted combination therapy
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2021-05-01
description	Triple negative breast cancer (TNBC) lack effective therapies. Here, through an in vivo genome-wide CRISPR screen in TNBCs, the authors identify tumorigenic functions for components of the mTORC1/2 complex and of the YAP/Hippo pathway, and demonstrate that pharmacological inhibition of mTOR and YAP reduces tumour growth in vivo.
url	https://doi.org/10.1038/s41467-021-23316-4
work_keys_str_mv	AT meioudai invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT gangyan invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT niwang invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT girijadaliah invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT ashlinmedick invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT sophiepoulet invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT julienboudreault invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT suhadali invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT sergioaburgos invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy AT jeanjacqueslebrun invivogenomewidecrisprscreenrevealsbreastcancervulnerabilitiesandsynergisticmtorhippotargetedcombinationtherapy
_version_	1721420579926441984

In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy

Similar Items